Facebook Instagram Linkedin Youtube
Home Search

cyxone - search results

If you're not happy with the results, please do another search
Cyxone comments on the clinical collaboration in the UK

Cyxone comments on the clinical collaboration in the UK

Cyxones CEO Carl-Magnus Högerkorp

Cyxone’s CEO gives a status update

Dendritic

Cyxone identifies target protein for rabeximod 

All sessions from BioStock Life Science Fall Summit 2023

Video from day 1 of BioStock Life Science Fall Summit 2023

Intervjubanner_BIMSeptember2023

Watch the interviews from BioStock Investor Meeting!

Companypresentations_BIM2023Sept

Watch the presentations from BioStock Investor Meeting!

Cyxone’s CEO comments on the US patent notice

Cyxone’s CEO comments on the US patent notice

BioStock Investor Meeting September 2023

BioStock Life Science Summit 2023

BioStock Life Science Summit 2023

Cyxone's CEO on the current state and the pipeline

Cyxone’s CEO on the current state and the pipeline

Watch the BioStock Life Science Fall Summit!

Cyxone reports Q3 and presents T20K

Cyxone reports Q3 and presents T20K

GSK terminates RA project

GSK terminates RA project

Cyxone on the phase IIb sttudy

Cyxone on the phase IIb study

October 12 - World Arthritis Day

October 12 – World Arthritis Day

NLSDays

NLSDays: Interviews with 10 interesting companies

Carl Magnus Högerkorp, interim CEO Cyxone

BioStock Investor Meeting: Interview with Cyxone

Erika Samuelsson new CDO at Cyxone

Erika Samuelsson new CDO at Cyxone

Cyxone_CarlMagnusHogerkorp_BioStockInvestorMeeting

BioStock Investor Meeting: Cyxone presents

Cyxone looks forward to study start

Cyxone looks forward to study start

Cyxone comments on scientific T20K article

Cyxone comments on scientific T20K article

Summit watch all presentations and interviews

BioStock Life Science Fall Summit 2022

BioStock Investor Meeting, September 14

New IR force at Cyxone

New IR force at Cyxone

New management in Cyxone

New management at Cyxone

Top five life science stocks during the first half-year

Biotech companies traded below cash

Cyxone focuses on the RA programme

Cyxone focuses on the RA programme

RA

RA patients in great need of new treatment options

Cyxone about the advancements in the T20K project

Cyxone about the advancements in the T20K project

Cyxone enters EOA with a CRO

Cyxone’s CRO agreement signal phase IIb RA trial is moving forward...

Cyxone updates on study results

BioStock Studio: Cyxone comments on the Covid-19 study result

Pre-clinical data indicates wider use for Cyxone's T20K

Pre-clinical data indicates wider use for Cyxone’s T20K in MS

BIO-Europe

Eight CEOs on their expectations at BIO-Europe

October 12th is World Arthritis Day

Cyxone has closed recruitment to the phase II Covid-19 trial

Cyxone and MedUni Vienna is exploring T20K

Cyxone is exploring new treatment possibilities for T20K

Cyxone’s new management in place for the next phase

Cyxone is looking forward to an eventful autumn

CombiGene’s new Chairman on visions for the future

BioStock Studio: Tara Heitner is ready to take Cyxone to the...

Cyxone has gathered new force

Awareness around arthritis raised for the 24th consecutive year

Cyxone announces expanded plans for Rabeximod

Aptahem’s founder is back – now as Chairman of the Board

Cyxone comments positive toxicological results

Cyxone attracts funding and files for new patents

Regulatory approval and up-listing for Cyxone

New COO brings extensive immunology experience to Cyxone

Spotlight on MS

Innovation in focus at BioStock Life Science Spring Summit 2021

Cyxone expands possibilities for T20K in MS

Cyxone joins forces with leading rheumatoid arthritis expert

Progress in Q4 sets tone for Cyxone in 2021

Cyxone’s Covid-19 trial with Rabeximod initiated in Europe

Watch company presentations & panels from the BioStock Life Science Summit...

Strong line-up at the BioStock Life Science Summit 2020

© BioStock 2025